Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.49 (reverse transcriptase)
 31,746 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Delavirdine (Rescriptor) is available through an expanded access program. Pharmacia & Upjohn's non-nucleoside reverse transcriptase inhibitor works in combination with AZT to reduce viral loads and increase CD4 counts. Effects are sustained for as long as a year. Its most common side effect is rash.
 ...
PMID:Expanded access for delavirdine. 1136 26

Upjohn Pharmacia started an expanded access program for delavirdine (Rescriptor) for patients with CD4 cell counts below 300 who are failing other therapies and receiving at least one other antiretroviral drug. Delavirdine, a non-nucleoside reverse transcriptase inhibitor, has been found to be synergistic with other antiretrovirals such as AZT and ddI.
 ...
PMID:Delavirdine expanded access program. 1136 51

A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine (Rescriptor) and nevirapine (Viramune) are described, including drug interactions, trial results, and the potential for resistance.
 ...
PMID:A new class of anti-HIV drugs. 1136 16

On September 27, 1996, the Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee meets to consider licensing the non-nucleoside reverse transcriptase inhibitor (NNRTI), delavirdine (Rescriptor). How both delavirdine and nevirapine, another NNRTI, affect the body's metabolism of protease inhibitors is an issue that remains unresolved. Pharmacia & Upjohn released preliminary results of combining delavirdine with the three marketed protease inhibitors: saquinavir, ritonavir, and indinavir. Tests show delavirdine raised saquinavir levels sixfold, had no effect on ritonavir, and doubled the effective dose of indinavir.
 ...
PMID:Delavirdine/protease inhibitor interactions. 1136 39

The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) for HIV-1 treatment in March. Delavirdine becomes the second non-nucleoside reverse transcriptase inhibitor approved; the first was nevirapine. The drug must be used in antiretroviral combinations because of resistance problems associated with using it alone. Delavirdine's primary side effect is skin rash, occasionally severe enough to cause permanent discontinuation of the treatment. The approval follows weak clinical data; further clinical testing is called for. Cost is relatively low at $2,250 annually.
 ...
PMID:Delavirdine (Rescriptor) approved. 1136 52

Delavirdine (Rescriptor), a non-nucleoside reverse transcriptase inhibitor, has received Food and Drug Administration (FDA) approval. Delavirdine has been studied in combination with other antiretrovirals in more than 2,400 patients. The drug is well tolerated, with skin rash being the most common side effect. The annual cost of treatment with Rescriptor is $2,250, with some minimal discounts available through AIDS Drug Assistance Programs.
 ...
PMID:Delavirdine gets FDA approval. Food and Drug Administration. 1136 63

The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) under its accelerated approval guidelines. The non-nucleoside reverse transcriptase inhibitor has drawn criticism from AIDS activists, who contend that it lacks potency, that current safety data is insufficient, and that future trials will be flawed. Pharmacia & Upjohn, the manufacturer, acknowledges many unknowns about the drug, but believes that there is a role for delavirdine in the treatment arsenal. One major concern is related to cross-resistance; use of delavirdine may decrease viral load while allowing patients to defer treatment with protease inhibitors.
 ...
PMID:Delavirdine gets the green light. 1136 19

The Food and Drug Administration (FDA) has granted accelerated approval for delavirdine (Rescriptor) for use in combination with other anti-HIV drugs. The non-nucleoside reverse transcriptase inhibitor (NNRTI) inhibits the virus through binding with the enzyme and may be synergistic with AZT and ddC. Interim test results have reported viral load reductions with combination therapy. There is no data related to survival or incidence of AIDS-related illnesses. There are few side effects associated with the drug, and its cost is significantly below that of protease inhibitors.
 ...
PMID:Delavirdine gains approval as second NNRTI for anti-HIV combination regimens. 1136 39

Results from a clinical trial of 718 participants, 139 of them women, indicate that women experience 1.8 times higher concentrations of delavirdine (Rescriptor) than do men. Women's smaller body size increases the dose per kilogram ratio compared to men, although pharmacokinetic studies have not demonstrated a gender difference in metabolism. The main side effect caused by delavirdine, a non-nucleoside reverse transcriptase inhibitor produced by Pharmacia and Upjohn, is a temporary rash that disappears without changing the treatment.
 ...
PMID:Delavirdine levels in women. 1136 81

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the latest drugs used to treat HIV infection. Three NNRTIs are introduced: Viramune (nevirapine), Rescriptor (delavirdine), and Viracept (nelfinavir). Recommended doses, rates of absorption, side effects, distribution throughout the body, clinical studies, reactions with other drugs, and how the drugs are metabolized are given. A list of agents that may inhibit the effect of Rescriptor and Viracept, such as antihistamines, antibiotics and anti-convulsions, is presented.
 ...
PMID:[New combination medications]. 1136 1


1 2 Next >>